Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 6, 2004, Pages 593-599

  Winter, J ^a,d   Walker, A ^b   Shapiro, D ^a   Gaffney, D ^c   Spooner, R J ^a   Mills, P R ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; ENTERITIS; ENZYME ACTIVITY; GENE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HEALTH CARE COST; HUMAN; LEUKOPENIA; MEDICAL DECISION MAKING; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; THIOPURINE METHYLTRANSFERASE GENE;

ADULT; AZATHIOPRINE; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 4644241129     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02124.x     Document Type: Article

References (26)

1. Pearson DC, May GR, Pick G, Sutherland AR. Azathioprine for maintenance of remission in Crohn's disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley and Sons, Ltd.
2. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley and Sons, Ltd.
3. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine-s-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-14.
4. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62.
5. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine s-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
6. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-50.
7. Schwab M, Schaffler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine s-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36.
8. Szumlanski C, Weinshilboum RM. Sulfsalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9.
9. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 464-75.
10. Lennard L. Clinical implications of thiopurine methyltransferase - optimisation of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20: 527-31.
11. Marra C, Esdaile J, Aslam HA. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyl-transferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29: 2507-12.
12. Black AJ, McLeod HL, Capell H, et al. Thiopurine methyl-transferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-8.
13. Suarez-Alamazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley and Sons, Ltd.
14. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
15. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
16. Present DH, Meltzer SJ, Krumholtz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long term toxicity. Ann Intern Med 1989; 111: 641-9.
17. Bouhnik Y, Lemann M, Mary JY, et al. Long term follow up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-9.
18. Qasim A, Seery J, Buckley M. TPMT in the treatment of inflammatory bowel disease with azathioprine (letter). Gut 2003; 52: 767-74.
19. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine-S-methyl-transferase genotype does not predict adverse reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 395-400.
20. Scottish Health Service Costs. Year Ending 31st March 2003. The Costs Book 2003. Information and Statistics Division of the Common Services Agency, http://www.isdscotland.org/ isd/info3.jsp. Last accessed 28 July 2004.
21. Office for National Statistics Autumn 2003. Expectation of Life (in years) at Birth and Selected Age, 1981 Onwards: Population Trends 114. http://www.census2001.gov.uk/ STATBASE/Expodata/Spreadsheets/D8625.csv. Last accessed 28 July 2004.
22. Pickin DM, McCabe CJ, Ramsay LE, et al. Cost effectiveness of HMG CoA reductase inhibitor (Statin) treatment relates to the risk of coronary heart disease and the cost of drug treatment. Heart 1999; 82: 325-33.
23. National Institute for Clinical Excellence. Interferon-alfa (Pegylated and Non-pegylated) and Ribavirin for the Treatment of Chronic Hepatitis C. Technology Appraisal Number 75. January 2004, http://www.nice.org.uk. Last accessed 28 July 2004.
24. National Institute for Clinical Excellence. Full Guidance for the Use of Infliximab in Crohn's Disease. Technology Appraisal Number 40. May 2002, http://www.nice.org.uk.
25. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low dose azathioprine. Aliment Pharmacol Ther 2002; 16: 389-98.
26. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine s-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-2.